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Background: Tumour budding has been reported to reflect invasiveness, metastasis and unfavourable prognosis in colorectal
cancer. The aim of the study was to examine the relationship between tumour budding and clinicopathological characteristics,
tumour microenvironment and survival in patients with primary operable colorectal cancer.
Methods: A total of 303 patients from a prospective data set of patients with primary operable colorectal cancer were included in
the study. The presence of budding was determined through assessment of all tumour-containing H&E slides and the number of
tumour buds was counted using a 10 high-powered field method. Routine pathologic sections were used to assess: tumour
necrosis, the tumour inflammatory cell infiltrate using Klintrup–Makinen (KM) grade and tumour stroma percentage (TSP)
combined as the Glasgow Microenvironment Score (GMS).
Results: High-grade tumour budding was present in 39% of all tumours and in 28% of node-negative tumours respectively. High-
grade budding was significantly associated with T stage (Po0.001), N stage (Po0.001), TNM stage (Po0.001), serosal involvement
(Po0.001), venous invasion (Po0.005), KM grade (P¼ 0.022), high tumour stroma (Po0.001) and GMS (Po0.001). Tumour budding
was associated with reduced cancer-specific survival (CSS) (HR¼ 4.03; 95% confidence interval (CI), 2.50–6.52; Po0.001),
independent of age (HR¼ 1.47; 95% CI, 1.13–1.90; P¼ 0.004), TNM stage (HR¼ 1.52; 95% CI, 1.02–2.25; P¼ 0.040), venous invasion
(HR¼ 1.73; 95% CI, 1.13–2.64; P¼ 0.012) and GMS (HR¼ 1.54; 95% CI, 1.15–2.07; P¼ 0.004).
Conclusions: The presence of tumour budding was associated with elements of the tumour microenvironment and was an
independent adverse prognostic factor in patients with primary operable colorectal cancer. Specifically high tumour budding
stratifies effectively the prognostic value of tumour stage, venous invasion and GMS. Taken together, tumour budding should be
assessed routinely in patients with primary operable colorectal cancer.
Colorectal cancer is a leading cause of cancer-related deaths worldwide
with up to 50% of patients dying of recurrent disease within 5 years
(Hyslop and Waldman, 2013). Although the TNM staging system
forms the basis of pathological staging in patients with colorectal
cancer, additional prognostic markers are required to improve the
prediction of likely outcome and therefore the management of patients.
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Over the last decade, tumour budding has gained momentum as
a possible marker of aggressive tumour behaviour and therefore a
supplement to the current TNM staging system, classified as an
‘additional’ prognostic factor in colorectal cancer by the American
Joint Committee on Cancer and International Union against
Cancer (AJCC/UICC) (Compton, 2006).
Tumour budding has been defined as the presence of isolated
single cells or small clusters of cells composed of up to five cells
(Ueno et al, 2002). Tumour budding is proposed to reflect the
process of epithelial–mesenchymal transition (EMT) whereby
highly differentiated epithelial mucosal cells develop to invasive
phenotypes (Zlobec and Lugli, 2010). Tumour budding appears to
be associated with adverse clinicopathological characteristics and
poor outcome and most studies report tumour budding as a
prognostic factor independent of other tumour features (van Wyk
et al, 2015).
To date, the tumour microenvironment has mainly been
described as a host immune reaction represented by peri-
and intratumoural immune cell infiltrates (Roxburgh and
McMillan, 2012) and the amount of stroma in the tumour
(Mesker et al, 2007).
These have recently combined in a tumour microenvironment
score, the Glasgow Microenvironment Score (GMS) (Park et al,
2015).
The aim of the present study was examine the relationship
between tumour budding, tumour microenvironment and survival
in patients with primary operable colorectal cancer.
PATIENTS AND METHODS
Patients. From a prospective database of patients with colorectal
cancer who underwent potentially curative resection between 1997
and 2008 in a single surgical unit at the Glasgow Royal Infirmary,
303 patients were included in the study. Patients who had
metastatic disease at diagnosis or underwent neoadjuvant therapy
and patients who died within 30 days of surgery were excluded.
Tumours were staged according to the fifth edition of the
AJCC/UICC-TNM staging system. Local ethical committee
approval was granted.
Histopathology
Venous invasion. Only extramural vascular invasion was
recorded. Venous invasion (VI) was assessed routinely with
elastica since 2003. Before 2003, VI was retrospectively stained
with elastica (Roxburgh et al, 2010).
Budding. The H&E slides containing the highest number of
budding foci were selected. Tumour sections were scanned using a
Hamamatsu Nano Zoomer (Welwyn Garden City, UK) at  20
magnification, and visualisation was carried out using the Slide
path Digital Image Hub, version 4.0.1 (Slide path, Leica Bio
Systems, Milton Keynes, UK). For quantification, the areas with the
highest density of peritumoural budding was selected under
scanning magnification and the number of tumour buds (tumour
cells with up to five nuclei or single tumour cells) were counted in
10 high-power fields (10 HPFs), as first described by Horcic et al
(2013) and Karamitopoulou et al (2013). Size of field (1 HPF per 1
grid) was 50 mm (Figure 1A). The total number of buds was used
for analysis. To ensure reliability, co-scoring of 25 randomly
selected cases (10HPFs) was carried out by HCvW and consultant
pathologist JJG. The interobserver intraclass correlation coefficient
(ICCC) for the scores was 0.766 (Po0.001). The remaining slides
were scored by HCvW and these results were used in the analysis.
Tumour necrosis. Tumour necrosis was graded semiquantitatively
as ‘absent’ (none), ‘focal’ (o10% of tumour area), ‘moderate’
(10–30%) or ‘extensive’ (430%) as previously described (Richards
et al, 2012).
Klintrup–Makinen grade. Klintrup–Makinen (KM) grade was
used to assess the generalised inflammatory infiltrate semiquanti-
tatively. The H&E-stained sections of the deepest point of tumour
invasion were used, whereby inflammatory cell density at the
invasive margin was graded using a four-point scale and
subsequently classified as low grade (no increase or mild/patchy
increase in inflammatory cells) or high grade (prominent
inflammatory reaction forming a band at the invasive margin, or
florid cup-like infiltrate at the invasive edge with destruction of
cancer cell islands) as previously described (Klintrup et al, 2005;
Roxburgh et al, 2009).
Tumour stroma percentage. Tumour stroma percentage (TSP)
was assessed semiquantitatively using full sections of the deepest
point of tumour invasion; the proportion of stroma was calculated
as a percentage of the visible field, excluding areas of mucin
deposition or necrosis.
Tumours were subsequently graded as low TSP (50%) or high
TSP (450%) as previously described (Park et al, 2014).
Glasgow Microenvironment Score. Glasgow Microenvironment
Score is a cumulative prognostic score that combined KM grade
and TSP and has shown to have independent prognostic value.
Scores used for GMS: 0 (KM strong), 1 (KM weak/low TSP) and 2
(KM weak/high TSP) (Park et al, 2015).
MMR protein expression. Expression was reported as MMR
proficient (strong nuclear staining with positive immune cells) or
MMR deficient (staining intensity is either weak or patchy with
normal immune cell infiltrate, or negative with complete loss of
expression and normal immune cell expression). Methods used
were as previously described (Park et al, 2016).
Statistical analysis. An optimal cutoff score for the determination
of ‘high-grade’ budding was performed by a receiver operating
characteristic curve analysis with cancer-specific survival (CSS) as
endpoint.
The w2 test was used to examine associations between
clinicopathological data and the presence of tumour budding.
Survival curves were constructed with the Kaplan–Meier method
and the influence of a given parameter on survival was assessed
with the log-rank test. Multivariate survival analysis with
calculation of hazard ratios (HRs) was performed using Cox’s
regression. A stepwise backward procedure derived a final model of
variables with a significant independent relationship. Deaths up to
15 March 2013 were included in the analysis. The P-values of
p0.05 were considered as statistically significant. Statistical
analysis was performed using the SPSS software version 21 (SPSS
Inc., Chicago, IL, USA).
RESULTS
Patient characteristics and pathologic variables. The study
comprised 303 patients with the mean patient age at the time of
resection of 68 years (range, 32–98 years) with 52% of patients as
males. Of the tumours, 76% occurred in the colon and 24% in the
rectum.
In terms of T stage, tumour invaded to the submucosa in 6 (2%),
to muscularis propria in 22 (7%), to subserosa in 188 (62%) and to
peritoneum in 87 (29%) patients. No positive lymph nodes were
found in 197 (65%) patients, 1–3 lymph nodes contained tumour
in 85 (28%) patients, and X3 lymph nodes were positive in 21
(7%) patients. Of the tumours, 87% were well and moderately
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differentiated, whereas 13% were poorly differentiated. Of the
tumours, 79 (26%) had serosal involvement, whereas in 22 (7%)
resection margins were involved. Venous invasion was present in
41% of colorectal tumours and in 35% of the 197 node-negative
tumours. Of the patients, 76 (25%) received adjuvant therapy and
51% of patients with TNM stage III received adjuvant
chemotherapy.
Determination of optimal score for high-grade budding. The
total bud count per 10 HPFs varied from 0 to 63 buds. In order to
identify the threshold for the number of buds, ROC analysis was
carried out. The distribution of tumour buds is shown in Figure 1B
and the optimal threshold of buds was derived from the ROC
analysis (Figure 1C; point of inflection¼ 20 buds; AUC¼ 0.663;
95% confidence interval (CI), 0.597–0.729; Po0.001).
Incidence of tumour budding and association of budding with
clinicopathologic variables. The overall detection rate for high-
grade budding was 39% and 28% for the whole and node-negative
cohort, respectively. High-grade budding was associated with
T stage (Po0.001), N stage (Po0.001) and TNM stage (Po0.001).
In terms of tumour characteristics, high-grade budding was
associated with serosal involvement (Po0.001), VI (Po0.01),
KM grade (Po0.05), TSP (Po0.001) and GMS (Po0.001;
Table 1).
Of the 215 patients who had MMR status assessed, 63 out of 74
(85%) MMR-competent patients had high tumour budding in
comparison with 11 out of 74 (15%) MMR-deficient patients
(P¼ 0.592).
The relationships between clinicopathological characteristics of
node-negative colorectal tumours and high grade budding are
shown in Supplementary Table 1. High-grade budding was
associated with T stage (Po0.010), serosal involvement
(Po0.010), VI (Po0.05), KM grade (Po0.05), TSP (Po0.001)
and GMS (Po0.001).
Role of tumour budding as prognostic factor. The relationships
between clinicopathological characteristics of colorectal tumours
and CSS are shown in Table 2. Median follow-up was 61 (26–95)
months during which there were 187 deaths, 89 from cancer. On
univariate analysis, age (Po0.018), T stage (Po0.001), N stage
(Po0.001), TNM stage (Po0.001), VI (Po0.001), GMS
(Po0.001) and tumour budding (Po0.001) were associated with
reduced CSS.
On multivariate analysis, age (HR¼ 1.47; 95% CI, 1.13–1.90,
P¼ 0.004), TNM stage (HR¼ 1.52; 95% CI, 1.02–2.25; P¼ 0.040),
VI (HR¼ 1.73; 95% CI, 1.13–2.64; P¼ 0.012), GMS (HR¼ 1.54;
95% CI, 1.15–2.07; P¼ 0.004) and tumour budding (HR¼ 4.03;
95% CI, 2.50–6.52; Po0.001) were independently associated with
reduced survival.
In TNM stage II disease, low and high tumour budding was
associated with 5-year survival/s.e. of 82% (5) and 36% (8)
(Po0.001). In TNM stage III disease, low and high tumour
budding was associated with 5-year survival/s.e. of 71% (9) and
31% (7) (Po0.001; Figure 2A and B).
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Figure 1. Assessment of tumour budding. (A) The 10 HPF method showing placement grid (1 HPF), (B) distribution of tumour buds and (C) ROC
analysis.
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Table 1. The relationship between tumour budding and clinicopathological characteristics in patients with primary operable
colorectal cancer (n¼303)
All,
n¼297 (%)
Low budding,
n¼185 (61%)
High budding,
n¼118 (39%) P-value
Host characteristics
Age (years)
o65 103 (34) 63 (34) 40 (34) 0.423
65–74 101 (33) 67 (36) 34 (29)
475 99 (33) 55 (30) 44 (37)
Sex
Male 158 (52) 93 (50) 53 (45) 0.414
Female 145 (48) 92 (50) 65 (55)
Adjuvant therapy
No 227 (75) 147 (80) 80 (68) 0.030
Yes 76 (25) 38 (20) 38 (32)
Tumour characteristics
Tumour site
Colon 230 (76) 138 (75) 92 (78) 0.504
Rectum 73 (24) 47 (25) 26 (22)
TNM stage
I 21 (7) 17 (9) 4 (3) o0.001
II 176 (58) 125 (68) 51 (43)
III 106 (35) 43 (23) 63 (54)
T stage
1 6 (2) 5 (3) 1 (1) o0.001
2 22 (7) 16 (8) 6 (5)
3 188 (62) 129 (70) 59 (50)
4 87 (29) 35 (19) 52 (44)
N stage
0 197 (65) 142 (77) 55 (47) o0.001
1 85 (28) 36 (19) 49 (41)
2 21 (7) 7 (4) 14 (12)
Differentiation
Well/moderate 264 (87) 165 (89) 99 (84) 0.181
Poor 39 (13) 20 (11) 19 (16)
Tumour perforation
Absent 289 (95) 176 (95) 113 (96) 0.800
Present 14 (5) 9 (5) 5 (4)
Serosal involvement
Absent 224 (74) 153 (83) 71 (60) o0.001
Present 79 (26) 32 (17) 47 (40)
Resection margins
Clear 281 (93) 174 (94) 107 (91) 0.270
Involved 22 (7) 11 (6) 11 (9)
Lymph nodes
o12 Nodes 205 (68) 129 (70) 76 (64) 0.335
412 Nodes 98 (32) 56 (30) 42 (36)
Venous invasion
Absent 179 (59) 126 (64) 53 (50) 0.013
Present 124 (41) 71 (36) 53 (50)
Tumour necrosis
Absent 167 (55) 104 (56) 63 (53) 0.630
Present 136 (45) 81 (44) 55 (47)
MMR status (215)
MMR competent 187 (87) 124 (88) 63 (85) 0.562
MMR deficient 28 (13) 17 (12) 11 (15)
Tumour microenvironment
KM grade
Weak 197 (65) 111 (60) 86 (73) 0.022
Strong 106 (35) 32 (40) 32 (27)
Stroma area
Low 226 (75) 158 (85) 68 (58) o0.001
High 77 (25) 27 (15) 50 (42)
GMS
0 106 (35) 74 (40) 32 (27) o0.001
1 140 (46) 92 (50) 48 (41)
2 57 (19) 19 (10) 38 (32)
Abbreviations: GMS¼Glasgow Microenvironment Score; KM grade¼ Klintrup–Makinen grade; MMR¼mismatch repair; TNM¼ tumour, node, metastasis.
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In the absence of VI, low and high tumour budding was
associated with 5-year survival/s.e. of 82% (5) and 46% (8)
(Po0.001). In the presence of VI, low and high tumour budding
was associated with 5-year survival/s.e. of 78% (7) and 23% (7)
(Po0.001; Figure 2C and D).
In GMS¼ 0, low and high tumour budding was associated
with 5-year survival/s.e. of 84% (5) and 44% (12) (Po0.001).
In GMS¼ 1, low and high tumour budding was associated
with 5-year survival/s.e. of 74% (6) and 37% (9) (Po0.001).
In GMS¼ 2, low and high tumour budding was associated with
5-year survival/s.e. of 82% (9) and 21% (8) (Po0.001; Figure 3).
In the MMR-competent group, low and high tumour budding
was associated with 5-year survival/s.e. of 76% (5) and 34% (7)
(Po0.001). In the MMR-deficient group, low and high tumour
budding was associated with 5-year survival/s.e. of 80% (11) and
49% (16) (Po0.001). Tumour budding effectively stratified MMR-
competent status, but the numbers in the MMR-deficient group
were low (Supplementary Figure 1).
DISCUSSION
The results of the present study showed that tumour budding
was associated with TNM stage, serosal involvement, VI
and a weaker inflammatory cell infiltrate and more stroma.
Moreover, tumour budding was independently associated with
CSS. Taken together, these results suggest a complex relationship
between tumour budding and the tumour microenvironment
and disease progression in patients with primary operable
colorectal cancer.
In the present study, high-grade budding occurred in 39% of
tumours and in 28% of node-negative tumours and are consistent
with results from previous studies (Ueno et al, 2004; Ha et al, 2005;
Kevans et al, 2011; Betge et al, 2012). Tumour budding was
examined in H&E-stained sections with the 10 HPF method and
an optimal prognostic threshold for high-grade budding was
successfully implemented that yielded a cutoff (15–20 buds),
similar to previous reports (Prall et al, 2005; Wang et al, 2009;
Gujam et al, 2015).
The 10 HPF method using cytokeratin-stained slides
was developed and validated by Horcic et al (2013) and
Karamitopoulou et al (2013). As H&E slides are readily available,
the 10 HPF method (H&E) can potentially contribute to the long
overdue implementation of tumour budding in routine pathology
practice. Although previous work showed improved detection rates of
tumour budding with cytokeratin and in comparison with H&E, the
interobserver agreements are reported to be superior with cytokeratin
stains (Koelzer et al, 2015; Kai et al, 2016), and such immuno-
histochemistry appears not to improve the prognostic value (Suzuki
et al, 2009; Puppa et al, 2012; van Wyk et al, 2015). Therefore, where
the number of tumour buds identified is below a defined threshold,
cytokeratin may be useful to assist in the assessment of difficult cases
and training to introduce tumour budding into routine pathology
practice. This would be similar to the RCP recommendation for
routine clinical pathology assessment of VI.
In the present study tumour budding and the GMS were shown
to have independent prognostic value. There are a number of
potential difficulties in incorporating these measures into routine
clinical pathological practice. However, with tumour budding and
the GMS being measured in routine H&E slides, the additional
complexity is minimised. Moreover, it offers the possibility of
computerised assessment in the same slide that may minimise the
complexity and subjectivity of assessment. For example, an
automated assessment algorithm for the KM score in routine
H&E slides has been reported (Forrest et al, 2014). A similar
approach could be applied to tumour stroma and to tumour
budding in routine H&E slides.
Recently, Dawson et al (2014) proposed that in patients with
colorectal cancer, high-grade tumour budding was associated with
aggressive molecular and biological features. Budding tumour cells
have been proposed to undergo an EMT like event, losing
expression of epithelial differentiation markers while gaining the
capacity to express mesenchymal and stemness markers (Brabletz
et al, 2005). Grigore et al (2016) suggested that most EMT
processes in tumour buds are not complete and that tumour buds
undergo partial EMT, with at least a subset of tumours displaying a
true hybrid, single-cell E/M phenotype in their buds. Nevertheless,
the EMT can be triggered by a diverse set of stimuli including
growth factor signalling, tumour–stromal cell interactions and
hypoxia. According to Righi et al (2015), tumour budding is
associated with hypoxia induced by hypovascularisation at the
advancing front of colorectal cancer. Budding cells are proposed to
escape such hypoxia by expressing a HIF-1a-mediated hypoxic
tumour phenotype that increases their potential to bud and
disseminate, perhaps through VI.
In addition, it would appear that tumour budding is able to
degrade the peritumoural connective tissue, evading the host’s
Table 2. The relationship between tumour budding, clinicopathological characteristics and cancer-specific survival in patients
with primary operable colorectal cancer (n¼303)
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age (o65/65–75 years/475 years) 1.37 (1.06–1.78) 0.018 1.47 (1.13–1.90) 0.004
Sex (male/female) 0.97 (0.64–1.47) 0.890
Site (colon/rectum) 0.74 (0.44–1.26) 0.270
T stage (1/2/3/4) 1.98 (1.38–2.85) o0.001 –
N stage (0/1/2) 1.71 (1.27–2.29) o0.001 –
TNM (I/II/III) 2.25 (1.54–3.30) o0.001 1.52 (1.02–2.25) 0.040
Venous invasion (absent/present) 2.22 (1.46–3.39) o0.001 1.73 (1.13–2.64) 0.012
Tumour necrosis (absent/present) 1.43 (0.94–2.16) 0.095
MMR status 1.02 (0.49–2.15) 0.952
Tumour microenvironment
GMS (0/1/2) 1.99 (1.48–2.67) o0.001 1.54 (1.15–2.07) 0.004
Tumour budding (low/high) 5.97 (3.73–9.56) o0.001 4.03 (2.50–6.52) o0.001
Abbreviations: CI¼ confidence interval; GMS¼Glasgow Microenvironment Score; HR¼hazard ratio; MMR¼mismatch repair; TNM¼ tumour, node, metastasis.
BRITISH JOURNAL OF CANCER Prognostic implication of tumour budding
160 www.bjcancer.com |DOI:10.1038/bjc.2016.173
response and infiltrate lymphatic and blood vessels leading to local
and distant metastasis (Lugli et al, 2012; Koelzer et al, 2015).
Indeed, in the present study tumour budding was significantly
associated with more tumour stroma and a weaker inflammatory
cell infiltrate. These results might suggest that stromal elements
interact through signalling molecules that potentially drive tumour
budding and cancer progression (Hill et al, 2005).
Of particular interest is the association between tumour budding
and tumour microenvironment as it is not known whether tumour
budding is a result of the tumour microenvironment or whether it
causes changes in the tumour microenvironment. Although high-
grade tumour budding and the characteristics of the tumour
microenvironment (i.e., stromal infiltration and loss of the
conspicuous inflammatory cell infiltrate) may represent differing
end points of common precursor genetic pathways, one may occur
as a consequence of the other. Indeed, it was of interest that the
proportion of patients with high-grade tumour budding increased
significantly with increasing GMS (GMS0: 30% vs GMS2: 36%).
These results may suggest that tumour budding is a result of
changes in the tumour microenvironment rather than the cause.
As both tumour budding and the GMS were independently
associated with poor outcome, tumour budding was combined
with GMS as follows: high KM and low stroma percentage
and low budding¼ 0, low KM¼ 1, low KM and high stroma
percentage¼ 2, low KM and high stroma percentage and high
budding¼ 3. The combined GMS and tumour budding effectively
stratifies survival in patients with primary operable colorectal
cancer (HR¼ 2.16; 95% CI, 1.65–2.82; Po0.001; Figure 4).
The limitations of the present study were as follows: the study
was conducted at a single centre and therefore the results need to
be further validated before any definite change of practice can be
recommended and with reference to the pathogenetic relationship
between tumour budding and microenvironment, the selection of
H&E-stained sections of the deepest point of tumour invasion for
assessing inflammatory infiltrate and tumour stroma percentage, as
well as H&E slides containing the highest number of budding foci
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Figure 2. Relationship between budding and clinicopathological factors. (A and B) Relationship between high- and low-grade tumour budding
and cancer-specific survival in patients with TNM stage II and III primary operable colorectal cancer (Po0.001). (C and D) Relationship between
tumour budding, venous invasion and cancer-specific survival in patients with primary operable colorectal cancer (Po0.001).
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for tumour budding assessment that may act as confounding
factors for the interpretation of the results. Therefore, assessment
of the intratumour distance between the selected areas may be
useful to include in the analysis in future studies.
CONCLUSION
The assessment of tumour budding with H&E is reliable and
effectively risk stratifies patients with primary operable colorectal
cancer. Tumour budding can potentially be integrated into existing
staging systems and should be considered for implementation in
routine clinical practice. The results also suggest that the presence
of tumour budding is determined with the tumour microenviron-
ment and this relationship is worthy of further investigation.
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